微生物群体中耐药滞留菌的研究进展

摘要/Abstract

摘要： 微生物群体在受到抗微生物药物冲击后，绝大多数很快死亡，但是有小部分的微生物亚群（subpopulation）并不能被彻底清除，与传统意义上的耐药菌（resistant mutants）不同，这部分菌株并没有发生基因序列上的变化，因此收集这部分菌株再培养后，发现其最低抑菌浓度（MIC）并没有变化，这部分不能被彻底清除的微生物亚群被称为是滞留菌（persisters）。越来越多的证明表明滞留菌是慢性感染性疾病迁延不愈、症状反复的重要原因。该文将对滞留菌的生物学特征、产生机制、对药物的耐受机制及清除策略等内容作一综述。

关键词: 滞留菌, 耐受, 耐药菌

Abstract: Treated with a fatal dose of antibiotic,most microbial population will soon die,while some subpopulation cannot be eliminated and thus survive.Different from the traditional resistant mutants,these bacterial strains do not change as to their gene sequence.After the collection and reincubation of the bacterial strains,its been found that their minimal inhibitory concentration （MIC） remains the same.The subpopulation that cannot be eliminated thoroughly is known as persisters.More and more studies suggest that persisters seem to play the main role in the recalcitrance of chronic infections.This paper reviewed the biological characteristics and the generation mechanism of persisters and their tolerance mechanism to antibiotic,as well as the strategy to eliminate them.

Key words: persisters, tolerance, resistant mutants

中图分类号:

郭静. 微生物群体中耐药滞留菌的研究进展[J]. , 2015, 35(12): 1080-1084.

参考文献

[1] Bigger JW. Treatment of staphylococcal infections with penicillin by intermittent sterilisation[J]. Lancet, 1944, 244:497–500
[2] Spoering AL, Lewis K. Biofilms and planktonic cells of Pseudomonas aeruginosa have similar resistance to killing by antimicrobials[J]. J Bacteriol, 2001, 183(23): 6746-6751.
[3] Keren I, Kaldalu N, Spoering A, et al. Persister cells and tolerance to antimicrobials[J]. FEMS Microbiol Lett, 2004, 230(1): 13-18.
[4] Keren I, Shah D, Spoering A, et al. Specialized persister cells and the mechanism of multidrug tolerance in Escherichia coli[J]. J Bacteriol, 2004, 186(24): 8172-8180.
[5] Lewis K. Persister cells, dormancy and infectious disease[J]. Nat Rev Microbiol, 2007, 5(1): 48-56.
[6] Lewis K. Persister cells[J]. Annu Rev Microbiol, 2010, 64: 357-372.
[7] LaFleur MD, Kumamoto CA, Lewis K. Candida albicans biofilms produce antifungal-tolerant persister cells[J]. Antimicrob Agents Chemother, 2006, 50(11): 3839-3846.
[8] Ramage G, Wickes BL, Lopez-Ribot JL. Biofilms of Candida albicans and their associated resistance to antifungal agents[J]. Am Clin Lab, 2001, 20(7): 42-44.
[9] Lafleur MD, Qi Q, Lewis K. Patients with long-term oral carriage harbor high-persister mutants of Candida albicans[J]. Antimicrob Agents Chemother, 2010, 54(1): 39-44.
[10] Mulcahy LR, Burns JL, Lory S, et al. Emergence of Pseudomonas aeruginosa strains producing high levels of persister cells in patients with cystic fibrosis[J]. J Bacteriol, 2010, 192(23): 6191-6199.
[11] 贾奋,亓庆国.用线虫模型研究白念珠菌生物膜中滞留菌对抗真菌治疗效果的影响[J]. 中华微生物学和免疫学杂志,2011年，第31卷(第10期): 588-591页
[12] Balaban NQ, Merrin J, Chait R, et al. Bacterial persistence as a phenotypic switch[J]. Science, 2004, 305(5690): 1622-1625.
[13] Shah D, Zhang Z, Khodursky A, et al. Persisters: a distinct physiological state of E. coli[J]. BMC Microbiol, 2006, 6: 53.
[14] Allison KR, Brynildsen MP, Collins JJ. Heterogeneous bacterial persisters and engineering approaches to eliminate them[J]. Curr Opin Microbiol, 2011, 14(5): 593-598.
[15] Nystrom T. Stationary-phase physiology[J]. Annu Rev Microbiol, 2004, 58: 161-181.
[16] Luidalepp H, Joers A, Kaldalu N, et al. Age of inoculum strongly influences persister frequency and can mask effects of mutations implicated in altered persistence[J]. J Bacteriol, 2011, 193(14): 3598-3605.
[17] Walker GC. Understanding the complexity of an organism's responses to DNA damage[J]. Cold Spring Harb Symp Quant Biol, 2000, 65: 1-10.
[18] Dorr T, Lewis K, Vulic M. SOS response induces persistence to fluoroquinolones in Escherichia coli[J]. PLoS Genet, 2009, 5(12): e1000760.
[19] Dorr T, Vulic M, Lewis K. Ciprofloxacin causes persister formation by inducing the TisB toxin in Escherichia coli[J]. PLoS Biol, 2010, 8(2): e1000317.
[20] Balaban NQ, Gerdes K, Lewis K, et al. A problem of persistence: still more questions than answers?[J]. Nat Rev Microbiol, 2013, 11(8): 587-591.
[21] Johnson PJ, Levin BR. Pharmacodynamics, population dynamics, and the evolution of persistence in Staphylococcus aureus[J]. PLoS Genet, 2013, 9(1): e1003123.
[22] Kim Y, Wood TK. Toxins Hha and CspD and small RNA regulator Hfq are involved in persister cell formation through MqsR in Escherichia coli[J]. Biochem Biophys Res Commun, 2010, 391(1): 209-213.
[23] Wood TK, Knabel SJ, Kwan BW. Bacterial persister cell formation and dormancy[J]. Appl Environ Microbiol, 2013, 79(23): 7116-7121.
[24] Hazan R, Sat B, Engelberg-Kulka H. Escherichia coli mazEF-mediated cell death is triggered by various stressful conditions[J]. J Bacteriol, 2004, 186(11): 3663-3669.
[25] Schuster CF, Bertram R. Toxin-antitoxin systems are ubiquitous and versatile modulators of prokaryotic cell fate[J]. FEMS Microbiol Lett, 2013, 340(2): 73-85.
[26] Hong SH, Wang X, O'Connor HF, et al. Bacterial persistence increases as environmental fitness decreases[J]. Microb Biotechnol, 2012, 5(4): 509-522.
[27] Wang X, Wood TK. Toxin-antitoxin systems influence biofilm and persister cell formation and the general stress response[J]. Appl Environ Microbiol, 2011, 77(16): 5577-5583.
[28] Leung V, Levesque CM. A stress-inducible quorum-sensing peptide mediates the formation of persister cells with noninherited multidrug tolerance[J]. J Bacteriol, 2012, 194(9): 2265-2274.
[29] Patra P, Klumpp S. Population dynamics of bacterial persistence[J]. PLoS One, 2013, 8(5): e62814.
[30] Hauryliuk V, Atkinson GC, Murakami KS, et al. Recent functional insights into the role of (p)ppGpp in bacterial physiology[J]. Nat Rev Microbiol, 2015, 13(5): 298-309.
[31] Amato SM, Orman MA, Brynildsen MP. Metabolic control of persister formation in Escherichia coli[J]. Mol Cell, 2013, 50(4): 475-487.
[32] Gerdes K, Maisonneuve E. Bacterial persistence and toxin-antitoxin loci[J]. Annu Rev Microbiol, 2012, 66: 103-123.
[33] Nguyen D, Joshi-Datar A, Lepine F, et al. Active starvation responses mediate antibiotic tolerance in biofilms and nutrient-limited bacteria[J]. Science, 2011, 334(6058): 982-986.
[34] Bernal P, Molina-Santiago C, Daddaoua A, et al. Antibiotic adjuvants: identification and clinical use[J]. Microb Biotechnol, 2013, 6(5): 445-449.
[35] Drawz SM, Bonomo RA. Three decades of beta-lactamase inhibitors[J]. Clin Microbiol Rev, 2010, 23(1): 160-201.
[36] Bernal P, Llamas MA. Promising biotechnological applications of antibiofilm exopolysaccharides[J]. Microb Biotechnol, 2012, 5(6): 670-673.
[37] Flemming HC, Wingender J. The biofilm matrix[J]. Nat Rev Microbiol, 2010, 8(9): 623-633.
[38] Rendueles O, Kaplan JB, Ghigo JM. Antibiofilm polysaccharides[J]. Environ Microbiol, 2013, 15(2): 334-346.
[39] Valle J, Da Re S, Henry N, et al. Broad-spectrum biofilm inhibition by a secreted bacterial polysaccharide[J]. Proc Natl Acad Sci U S A, 2006, 103(33): 12558-12563.
[40] Ma L, Jackson KD, Landry RM, et al. Analysis of Pseudomonas aeruginosa conditional psl variants reveals roles for the psl polysaccharide in adhesion and maintaining biofilm structure postattachment[J]. J Bacteriol, 2006, 188(23): 8213-8221.
[41] Rendueles O, Travier L, Latour-Lambert P, et al. Screening of Escherichia coli species biodiversity reveals new biofilm-associated antiadhesion polysaccharides[J]. MBio, 2011, 2(3): e00043-00011.
[42] Asif M, Acharya M. Quorum sensing: A nobel target for antibacterial agents[J]. Avicenna J Med, 2012, 2(4): 97-99.
[43] Deep A, Chaudhary U, Gupta V. Quorum sensing and Bacterial Pathogenicity: From Molecules to Disease[J]. J Lab Physicians, 2011, 3(1): 4-11.
[44] Pan J, Bahar AA, Syed H, et al. Reverting antibiotic tolerance of Pseudomonas aeruginosa PAO1 persister cells by (Z)-4-bromo-5-(bromomethylene)-3-methylfuran-2(5H)-one[J]. PLoS One, 2012, 7(9): e45778.
[45] Pan J, Song F, Ren D. Controlling persister cells of Pseudomonas aeruginosa PDO300 by (Z)-4-bromo-5-(bromomethylene)-3-methylfuran-2(5H)-one[J]. Bioorg Med Chem Lett, 2013, 23(16): 4648-4651.
[46] Pan J, Xie X, Tian W, et al. (Z)-4-bromo-5-(bromomethylene)-3-methylfuran-2(5H)-one sensitizes Escherichia coli persister cells to antibiotics[J]. Appl Microbiol Biotechnol, 2013, 97(20): 9145-9154.
[47] Drissi F, Buffet S, Raoult D, et al. Common occurrence of antibacterial agents in human intestinal microbiota[J]. Front Microbiol, 2015, 6: 441.
[48] Chen X, Zhang M, Zhou C, et al. Control of bacterial persister cells by Trp/Arg-containing antimicrobial peptides[J]. Appl Environ Microbiol, 2011, 77(14): 4878-4885.
[49] Niepa TH, Gilbert JL, Ren D. Controlling Pseudomonas aeruginosa persister cells by weak electrochemical currents and synergistic effects with tobramycin[J]. Biomaterials, 2012, 33(30): 7356-7365.